Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments

Immunotherapy is changing the paradigm of multiple myeloma (MM) management and daratumumab is the first-in-class human monoclonal antibody targeting CD38 approved for the treatment of this malignancy. Daratumumab exerts anti-myeloma activity by different mechanisms of action as antibody-dependent ce...

Cijeli opis

Bibliografski detalji

Glavni autori:	Massimo Offidani, Laura Corvatta, Sonia Morè, Davide Nappi, Giovanni Martinelli, Attilio Olivieri, Claudio Cerchione
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2021-02-01
Serija:	Frontiers in Oncology
Teme:	daratumumab multiple myeloma relapsed refractory multiple myeloma newly diagnosed multiple myeloma anti CD38
Online pristup:	https://www.frontiersin.org/articles/10.3389/fonc.2020.624661/full
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!